A Phase 3 interventional study of Macular Laser Photocoagulation and Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Branch Retinal Vein Occlusion, sponsored by Regeneron Pharmaceuticals. Completed at 56 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-13.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one is the 3rd largest by enrollment, is one of 3 that started in 2012, is one of 4 in phase 3, and was the 3rd registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 10
First in 2009; this study’s year is marked. 3 started in 2012.
This study's enrollment of 183 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 21 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 21 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 3 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in patients with macular edema secondary to BRVO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following inclusion criteria include, but are not limited to:
Exclusion Criteria:
The following exclusion criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
Procedure: Macular Laser Photocoagulation
Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF
Best corrected visual acuity (BCVA) was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at every visit from baseline through week 24. Last observation carried forward (LOCF) method was used to impute missing data.
Time frame: Baseline to week 24
Change From Baseline to Week 24 in BCVA Score - LOCF
Best corrected visual acuity (BCVA) was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at every visit from baseline through week 24 - Last observation carried forward (LOCF) method was used to impute missing data.
Time frame: Baseline to Week 24
Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF
CRT was evaluated at every visit from baseline through week 24 using spectral domain Optical Coherence Tomography (OCT).
Time frame: Baseline to week 24
Change From Baseline in the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) Questionnaire Total Score at Week 24 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Time frame: Baseline to week 24
Participants with macular edema secondary to branch retinal vein occlusion (BRVO) involving the center of the macula in the study eye were eligible to participate in the study.
| Milestone | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| Started | 92 | 91 |
| Completed week 24 | 83 | 85 |
| Completed week 52 | 77 | 73 |
| Completed | 77 | 73 |
| Not completed | 15 | 18 |
| Withdrew: Adverse event | 0 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 11 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Other | 1 | 2 |
Best corrected visual acuity (BCVA) was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at every visit from baseline through week 24. Last observation carried forward (LOCF) method was used to impute missing data.
| participants | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF | 24 | 48 |
Best corrected visual acuity (BCVA) was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at every visit from baseline through week 24 - Last observation carried forward (LOCF) method was used to impute missing data.
| letters correctly read | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| Change From Baseline to Week 24 in BCVA Score - LOCF | 6.9 ± 12.91 | 17.0 ± 11.88 |
CRT was evaluated at every visit from baseline through week 24 using spectral domain Optical Coherence Tomography (OCT).
| microns | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF | -128.0 ± 195.02 | -280.5 ± 189.7 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
| scores on a scale | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| Change From Baseline in the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) Questionnaire Total Score at Week 24 - LOCF | 6.3 ± 12.34 | 7.7 ± 11.08 |
Collected over Through Week 52 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Macular Laser Photocoagulation Treatment (Control) | — | 10/92 (10.9%) | 30/92 (32.6%) |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | — | 13/91 (14.3%) | 25/91 (27.5%) |
| Event | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/92 | 2/91 |
| PneumoniaInfections and infestations | 1/92 | 2/91 |
| DehydrationMetabolism and nutrition disorders | 2/92 | 0/91 |
| Atrial fibrillationCardiac disorders | 0/92 | 1/91 |
| Atrioventricular block second degreeCardiac disorders | 0/92 | 1/91 |
| BradycardiaCardiac disorders | 0/92 | 1/91 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 1/91 |
| CardiomyopathyCardiac disorders | 0/92 | 1/91 |
| Cataract traumaticInjury, poisoning and procedural complications | 0/92 | 1/91 |
| Chest painGeneral disorders | 0/92 | 1/91 |
| Event | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
|---|---|---|
| Conjunctival haemorrhageEye disorders | 14/92 | 22/91 |
| HypertensionVascular disorders | 15/92 | 9/91 |
| NasopharyngitisInfections and infestations | 8/92 | 8/91 |
| Eye irritationEye disorders | 1/92 | 7/91 |
| Eye painEye disorders | 7/92 | 5/91 |
| Urinary tract infectionInfections and infestations | 7/92 | 3/91 |
| BronchitisInfections and infestations | 2/92 | 6/91 |
| Blood pressure increasedInvestigations | 5/92 | 4/91 |
Full analysis set (FAS): All enrolled subjects who received any investigational product, had a baseline best corrected visual acuity (BCVA) assessment, and at least 1 post-baseline BCVA assessment.
| Age, Continuous(years) | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Total |
|---|---|---|---|
| Mean | 63.9 ± 11.37 | 67.0 ± 10.41 | 65.5 ± 10.98 |
| Sex: Female, Male(Participants) | Macular Laser Photocoagulation Treatment (Control) | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Total |
|---|---|---|---|
| Female | 36 | 47 | 83 |
| Male | 54 | 44 | 98 |
The record gives a start of Apr 2012, a primary completion of Aug 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 3 months after primary completion. A results delay was requested in Jul 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept